Objective
Ahead Therapeutics is a biotechnology company developing a novel technology platform to treat autoimmune diseases. Regarding type 1 diabetes (T1D), our approach is designed to restore immune balance and protect the insulin-producing β-cells of the pancreas, potentially transforming the way autoimmune diseases are managed.
T1D occurs when the immune system mistakenly attacks β-cells, reducing the body’s ability to produce insulin and leading to lifelong insulin dependence. Current treatments focus on blood sugar management, but they do not address the root cause: the immune system’s dysfunction. Our technology aims to reprogram the immune system, stopping the β-cell attack and preserving their function. If successful, this could prevent the disease (T1D Stage 2 individuals) and could reduce or eliminate the need for external insulin therapy (T1D Stage 2 individuals), offering a long-term, disease-modifying solution for people living with T1D.
We are currently conducting preclinical studies on our T1D asset, laying the foundation for future human trials. The Breakthrough T1D IDDP grant will support critical development and optimization efforts before we submit an Investigational New Drug (IND) application to regulatory agencies. Our goal is to ensure the highest quality, safety, and efficacy standards for our therapy before moving to clinical trials.
Specifically, this funding will enable us to refine and strengthen our T1D therapy by focusing on three essential areas:
• Improve the liquid formulation of our T1D therapy by fine-tuning its composition and developing reliable tests to measure its stability and effectiveness. A well-characterized, consistent formulation is key to advancing toward clinical trials.
• Develop a freeze-dried (solid) version of the therapy that maintains the same effectiveness as the liquid form but is easier to store, transport, and manufacture at scale. A stable, long-lasting product will make the treatment more practical and widely available.
• Confirm that the final solid formulation interacts with the immune system, inducing specific tolerance through dendritic cells, monocytes, and B lymphocytes from people with T1D. These tests will confirm whether the therapy works as intended and support its progression toward human trials.
By addressing these key aspects in preclinical development, we aim to create a more effective, durable, and scalable therapy that can significantly improve the lives of people with T1D.
If successful, our work will:
• Provide a disease-modifying treatment rather than just managing symptoms.
• Prevent and contribute to T1D cure
• Offer a longer-lasting and more accessible treatment option.
• Pave the way for clinical trials, bringing this therapy closer to patients.
With the support of this grant, we can accelerate our research, refine our formulation, and generate critical preclinical data to position our therapy for regulatory approval. This will allow us to move confidently toward human trials and, ultimately, provide a transformative treatment option for individuals living with T1D.
Background Rationale
At Ahead Therapeutics, we are pioneering a groundbreaking approach to treating autoimmune diseases by harnessing the body's natural mechanisms for immune tolerance. Our proprietary technology platform is designed to restore immune balance, offering a potential tool for the prevention and cure for diseases where the immune system mistakenly attacks the body’s own cells.
The human immune system is essential for protecting us from infections and harmful invaders. However, in autoimmune diseases, the immune system loses its ability to distinguish between harmful pathogens and the body’s own tissues, leading it to attack healthy cells or tissues. This results in chronic inflammation and tissue damage, causing diseases like type 1 diabetes (T1D), multiple sclerosis, and rheumatoid arthritis, among others.
While current treatments for autoimmune diseases mainly focus on suppressing the immune system, they often come with serious side effects and do not address the underlying cause of the disease. Our approach offers a targeted solution—one that works with the immune system rather than shutting it down entirely.
Our technology is inspired by a fundamental biological process called efferocytosis, which is how the body naturally removes dying cells. Every day, billions of cells in our body complete their lifecycle and undergo apoptosis (cell death). Specialized immune cells called phagocytes engulf and clear away apoptotic cells. Normally, this process helps the immune system recognize that these dying cells are part of the body and should not trigger an immune attack. Therefore, training the immune system to recognize self-tissues and avoid autoimmunity.
At Ahead Therapeutics, we have developed a nanotechnology-based platform that mimics this natural tolerance mechanism to stop autoimmune attacks. Our approach, built on Antigen-Specific Immune Tolerance (ASIT) generation, uses specially designed PS-Liposomes that trick the immune system into recognizing and tolerating specific autoantigens—the proteins mistakenly targeted in autoimmune diseases.
Our platform is fundamentally different from existing treatments in several key ways:
• Disease-Specific Tolerance: Instead of broadly suppressing the immune system, our technology targets only the harmful autoimmune response, leaving the rest of the immune system intact to fight infections and diseases. It is a precision medicine mechanism that corrects only the defect causing the disease.
• Long-Term Effects: By mimicking the body's natural mechanisms, our therapy has the potential to provide long-lasting immune self-tolerance, reducing or even eliminating the need for chronic treatments.
• Safe and Scalable: Our liposome-based platform offers a non-toxic, biocompatible approach that can be adapted for multiple autoimmune diseases, making it a versatile and scalable solution.
At Ahead Therapeutics, we believe that the future of autoimmune disease treatment lies in restoring immune balance rather than suppressing it. Our technology has the potential to not only stop disease progression but also prevent autoimmune diseases from developing in the first place.
With continued research and development, our platform could lead to groundbreaking treatments for multiple autoimmune diseases, improving the lives of millions worldwide.
Description of Project
At Ahead Therapeutics, we are developing a breakthrough technology designed to treat autoimmune diseases by reprogramming the immune system to recognize and tolerate the body’s own tissues. Our innovative approach has the potential to stop the autoimmune attack in type 1 diabetes (T1D)—a condition where the immune system mistakenly destroys insulin-producing β-cells in the pancreas. Unlike existing treatments that focus solely on managing blood sugar levels, our immunotherapy aims to halt the disease at its source, offering a potential cure rather than lifelong insulin dependence.
Our proprietary technology platform is based on a natural immune tolerance mechanism that occurs in the body every day. When cells reach the end of their life cycle, they undergo a process called efferocytosis, signaling to the immune system that they should be removed without triggering an immune attack. A critical part of this process is phosphatidylserine (PS), a molecule that appears on the surface of dying cells, instructing immune cells to clear them safely.
Our therapy uses liposomes to deliver disease-specific autoantigens in a way that promotes tolerance rather than immune attack. By incorporating PS and autoantigens into our liposomes, we are able to train the immune system to tolerate β-cells as “self” and halt their destruction.
The Breakthrough T1D IDDP grant will support critical preclinical research to bring our therapy closer to human clinical trials. Our main objectives include:
1. Optimizing the Liquid Formulation – We will fine-tune our therapy’s composition to ensure it is stable, effective, and safe for future clinical use.
2. Developing a Freeze-Dried Version – Creating a solid formulation that maintains effectiveness while improving shelf life, ease of storage, and scalability.
3. Validating the final formulation in Human Immune Cells – Testing how the therapy interacts with dendritic cells, monocytes, and B lymphocytes from individuals with T1D to confirm its ability to suppress autoimmune activity and protect β-cells.
With this research, we aim to:
• Halt the autoimmune attack on β-cells, in an antigen-specific form and without affecting the homeostasis of the immune system
• Contribute to T1D prevention or reversal, depending on the stage of administration.
• Offer a safe, scalable, and long-lasting treatment that can be easily manufactured and distributed.
Our work aligns with the urgent need for disease-modifying therapies in T1D. By targeting the underlying autoimmune process, our therapy offers a transformative alternative to traditional insulin therapy. If successful, this approach could shift the standard of care, giving people with T1D a better quality of life and long-term disease control.
By demonstrating the ability to restore immune tolerance in T1D, our platform could pave the way for similar approaches in other autoimmune conditions. With continued support, we believe our technology has the potential to transform the treatment of autoimmune diseases, shifting from symptom management to addressing the root cause. This breakthrough could offer millions of people a future with less reliance on lifelong therapies and, in the case of T1D, a world where insulin dependence is no longer necessary.
Anticipated Outcome
With the support of the Breakthrough T1D grant, we expect to generate critical preclinical data that will directly shape the development of our T1D therapy. These experiments will allow us to refine the formulation, enhance stability, and validate the therapy’s immune effects, bringing us closer to clinical trial application. By addressing key technical and biological aspects, we aim to ensure our product is safe, effective, and scalable for future use in people.
One of the primary goals of this research is to develop an improved formulation with an extended shelf life, ensuring that the therapy remains stable and effective over time. Stability is a crucial factor in the development of any biologic therapy, as it affects manufacturing, distribution, and accessibility. A longer shelf life means the therapy will be easier to store, more widely available, and more cost-effective, making it a practical solution for both healthcare providers and individuals living with T1D.
A critical component of our study involves testing the new formulation in human samples to confirm its biological activity in an environment that closely mimics real-world conditions. To achieve this, we will analyze biomarkers of immune modulation that indicate whether the therapy is effectively regulating the immune system (T cell activation and cytokines modulation). These tests will provide early evidence of efficacy, allowing us to refine our approach before advancing to clinical trials.
Completing these studies will put us in a stronger position to advance to an Investigational New Drug (IND) submission, a key regulatory milestone before initiating human trials. By ensuring our therapy is stable and effective, we can move forward with greater confidence in its potential clinical success.
In addition to de-risking clinical trials, the data we generate will provide valuable insights that can guide future development of our technology platform to other autoimmune diseases. A well-characterized therapy with strong preclinical validation will have a higher likelihood of gaining regulatory approval, increasing its chances of reaching the people who need it most.
Ultimately, this research will help us develop a treatment that is practical, effective, and accessible—a significant step toward transforming how T1D is managed. With a strong scientific foundation, our work has the potential to reshape the future of T1D therapy, offering a disease-modifying solution that goes beyond insulin dependence.
Relevance to T1D
Type 1 diabetes (T1D) remains a significant unmet medical need, affecting millions of individuals worldwide. Despite advances in insulin therapy and glucose monitoring, there is still no cure, and people with T1D must navigate daily disease management while facing long-term health risks. Over time, individuals with T1D are at increased risk for kidney disease, nerve damage, cardiovascular complications, and other serious conditions.
A fundamental problem in T1D is the immune system’s attack on insulin-producing β-cells in the pancreas. This autoimmune response progressively reduces the body’s ability to produce insulin, leading to lifelong dependence on external insulin therapy. While insulin treatment has been life-saving, it does not address the root cause of the disease: immune system dysfunction.
Ahead Therapeutics’ technology is designed to intervene at a critical stage in T1D, restoring immune balance and preventing further β-cell destruction. Unlike current treatments that only manage blood sugar, our approach seeks to halt disease progression by reprogramming the immune system and stopping the attack of β-cells and preserving the body’s natural insulin production. If successful, this would represent a paradigm shift in T1D treatment—moving beyond symptom management to directly addressing the underlying autoimmune process.
By preserving β-cell function, our therapy has the potential to:
• Reduce or eliminate the need for external insulin by allowing the pancreas to continue producing its own insulin.
• Lower HbA1c levels and stabilize blood glucose control, reducing the risk of dangerous fluctuations.
• Reduce autoimmune activity, as measured by decreased T-cell responses and autoantibody levels.
• Offer a safer, more effective, and durable treatment, addressing a major gap in T1D therapeutics.
This would mean greater independence from insulin therapy, fewer disease-related complications, and a better quality of life for people living with T1D.
The Breakthrough T1D IDDP grant will directly support our efforts to make this vision a reality by funding key preclinical studies that are essential before advancing to human trials.
By generating robust preclinical data, we can move closer to regulatory approval and clinical trials, ultimately accelerating the development of a first-in-class therapy that could transform T1D treatment.
While our immediate focus is T1D, the insights gained from this research could extend to other autoimmune diseases, where immune system dysfunction leads to tissue damage. This grant will not only bring us closer to a breakthrough in T1D but also expand the potential impact of our technology platform across a range of immune-mediated diseases.
In summary, our work directly addresses one of the biggest challenges in T1D: stopping the immune attack on β-cells. Current treatments do not prevent the loss of β-cells, but our approach offers a real opportunity to preserve insulin production and change the course of the disease.
With the right support, we can bring a novel, life-changing therapy closer to those who need it most. By advancing our research and accelerating the development of a truly disease-modifying treatment, we aim to create a future where people with T1D no longer have to rely on insulin therapy—but instead, have a solution that targets the disease at its source.